Sciele enjoys six-year stock high

After yesterday's news hit that Atlanta-based Sciele Pharma would accept Japan's Shionogi's generous buyout offer, shares of the drug company's stocks jumped nearly 60 percent.

The deal, for $31 per share, will net Sciele $1.4 billion. Shionogi's offer was 61 percent above the stock price at market closure on Friday, but the stock closed at almost the offer price, at $30.68 per share on Tuesday. 

Sciele's stocks haven't sold for over $30 since the beginning of 2002.

- see the story at Forbes.com
- find out what Business Week says

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.